


IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/574,101</td> </tr> <tr> <td>§ 371 Date</td> <td>March 8, 2007</td> </tr> <tr> <td>First Named Inventor</td> <td>Bernat JUAN VIDAL</td> </tr> <tr> <td>Art Unit</td> <td>1624</td> </tr> <tr> <td>Examiner Name</td> <td>V. Balasubramanian</td> </tr> <tr> <td>Attorney Docket Number</td> <td>09605.0017-00000</td> </tr> </table>		Application Number	10/574,101	§ 371 Date	March 8, 2007	First Named Inventor	Bernat JUAN VIDAL	Art Unit	1624	Examiner Name	V. Balasubramanian	Attorney Docket Number	09605.0017-00000
Application Number	10/574,101																
§ 371 Date	March 8, 2007																
First Named Inventor	Bernat JUAN VIDAL																
Art Unit	1624																
Examiner Name	V. Balasubramanian																
Attorney Docket Number	09605.0017-00000																
Sheet	1	of	1														



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-2004/0006082 A1	01-08-2004	Harada et al.	
	2	US-6,750,232 B2	06-15-2004	Harada et al.	
	3	US-7,396,836 B2	07-08-2008	Harada et al.	
	4	US-2009/0030023 A1	01-29-2009	Harada et al.	
	5	US Appln. No. 12/521,133	Filed 06-25-2009	Laboratorios Almirall	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	6	WO 2005/040151 A1	05-06-2005	Fujisawa Pharmaceutical Co.		
	7	WO 2008/080461 A1	07-10-2008	Laboratorios Almirall, S.A.		

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
	8	International Search Report for International Application No. PCT/EP2007/010162 (WO 2008/080461) dated March 3, 2008.	
	9	King, FD "Bioisosteres, Conformational Restriction, and Pro-drugs - Case History: An Example of a Conformational Restriction Approach," Principles and Practice, Chapter 14: 208-225 (1994).	
	10	Office Action dated June 19, 2009 for Application No. 11/997,048.	

Examiner Signature	/Venkataraman Balasubramanian/	Date Considered	08/17/2009
--------------------	--------------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

the PTO did not receive the following:  
 cited item(s) NPL No. 10  
 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /VB/